Why might statins prevent venous thromboembolism: what needs to be done to know more?
Dyslipidaemia may be a risk factor for venous thromboembolism and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may be protective. The current review outlines the cumulative evidence from both the basic and epidemiologic sciences for why this might be so and offers some directions for future research.
Ray
Joel G
JG
Department of Medicine, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada. rayjg@mcmaster.ca
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D013923:Thromboembolism / Q000097:blood / Q000201:enzymology / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000097:blood / Q000201:enzymology / Q000517:prevention & control*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors